TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30677455

Group type: EXPERIMENTAL
Intervention: Rezūm System thermal therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Crossover subjects from control to active treatment
Number of subjects: 188
Study: 28766084

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 598

Group type: COMPARATOR
Intervention: Standard usual care
Number of subjects: 598
Study: 25495505

Group type: EXPERIMENTAL
Intervention: Restrictive group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 23984182

Group type: EXPERIMENTAL
Intervention: EFT treatment
Number of subjects: 96
Study: 21458532

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT), 40 sessions
Number of subjects: 87

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 87
Study: 18059423

Group type: EXPERIMENTAL
Intervention: Cleaning intervention
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cleaning and education interventions
Number of subjects: 47
Study: 16099416

Group type: EXPERIMENTAL
Intervention: Recognition Heuristic (RH) with additional cue information for recognized cities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recognition Heuristic (RH) without additional cues
Number of subjects: 0
Study: 12571183

Group type: EXPERIMENTAL
Intervention: Recombinant FSH for ovulation induction
Number of subjects: 41
Study: 11458246

Group type: EXPERIMENTAL
Intervention: HIV-1 positive women
Number of subjects: 638

Group type: COMPARATOR
Intervention: HIV-1 negative women
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 638
Study: 9433422

Group type: EXPERIMENTAL
Intervention: NT‐ANP concentration
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: BNP concentration
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: BNP concentration of 17.9 pg/mL or more
Number of subjects: 1252
Study: 8017305

Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization with heparin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Peripheral angiography without heparin
Number of subjects: 43
Study: 2598979

Group type: EXPERIMENTAL
Intervention: Glucagon with surfactants (9-lauryl ether as spray, sodium glycocholate as spray or powder)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human calcitonin with surfactants (dihydrofusinate as spray or powder, glycocholate as spray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Powders and spray solutions of glucagon and calcitonin
Number of subjects: 0
Study: 4885026

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 11
Study: 7013055

Group type: EXPERIMENTAL
Intervention: sulindac 100 mg b.i.d. (plus indomethacin placebo)
Number of subjects: 42

Group type: COMPARATOR
Intervention: indomethacin 25 mg t.i.d. (plus sulindac placebo)
Number of subjects: 42
Study: 31006118

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 42
Study: 29105247

Group type: EXPERIMENTAL
Intervention: Musicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmusicians
Number of subjects: 0
Study: 26871805

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine 0.5 mg/kg (group K)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal saline (group S)
Number of subjects: 104
Study: 25603666

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed primary closure
Number of subjects: 158
Study: 22428119

Group type: EXPERIMENTAL
Intervention: Naïve subjects (test group) allowed to gaze freely during various tasks (photographic images, video, computer tasks, walking)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects instructed to gaze at bright features and dark features in phase 1
Number of subjects: 20
Study: 20204984

Group type: EXPERIMENTAL
Intervention: Standard care plus psychological preparation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 85
Study: 17586452

Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Meglumine antimoniate (20mgSb(5)/kg body weight daily for 14 days)
Number of subjects: 63
Study: 15637501

Group type: EXPERIMENTAL
Intervention: Ginger (various forms, dosage not specified)
Number of subjects: 4
Study: 12000468

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 21
Study: 9790462

Group type: EXPERIMENTAL
Intervention: Dilatation plus Nd‐YAG laser therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dilatation alone
Number of subjects: 15
Study: 9363233

Group type: EXPERIMENTAL
Intervention: Vaginal capsules containing seminal plasma
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (lubrication jelly)
Number of subjects: 87
Study: 2533449

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 333643

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate (Plaquenil)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 30955461

Group type: EXPERIMENTAL
Intervention: Propofol or dexmedetomidine for sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic prevention of delirium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of delirium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies to improve sleep
Number of subjects: 0
Study: 28388136

Group type: EXPERIMENTAL
Intervention: Phase modulated saturation pulse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other dipolar recoupling sequences
Number of subjects: 0
Study: 26040620

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 63
Study: 23379498

Group type: EXPERIMENTAL
Intervention: Pulse high-volume hemofiltration (PHVHF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 30
Study: 21325466

Group type: EXPERIMENTAL
Intervention: Drospirenone/ethinyl estradiol (3 mg/30 μg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg)
Number of subjects: 46
Study: 19802544

Group type: EXPERIMENTAL
Intervention: Qiming Granule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium dobesilate capsule
Number of subjects: 0
Study: 16763247

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (3 times daily for 5 days)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (3 times daily for 5 days)
Number of subjects: 119
Study: 15642961

Group type: EXPERIMENTAL
Intervention: High dose of Artemotil (4.8 mg/kg on day 0 at 0 hours, 1.6 mg/kg at 6 hours, and 1.6 mg/kg/day on days 1-4)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low dose of Artemotil (3.2 mg/kg on day 0 and 1.6 mg/kg/day on days 1-4)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patient 151 (high dose regimen)
Number of subjects: 56
Study: 11524639

Group type: EXPERIMENTAL
Intervention: Face-to-face instruction
Number of subjects: 210

Group type: COMPARATOR
Intervention: Video-based instruction
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 210
Study: 9395429

Group type: EXPERIMENTAL
Intervention: Early-diagnosis group (neonatal screening)
Number of subjects: 650341

Group type: COMPARATOR
Intervention: Control group (standard diagnostic methods)
Number of subjects: 650341
Study: 11067179

Group type: EXPERIMENTAL
Intervention: Project Towards No Tobacco Use curricula (four different school-based tobacco use prevention curricula)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Project Towards No Tobacco Use curricula
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control schools (systematic health education delivered by school personnel)
Number of subjects: 48
Study: 3531110

Group type: COMPARATOR
Intervention: XRT + BCNU
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: MISO + XRT + BCNU
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 293
Study: 31657712

Group type: EXPERIMENTAL
Intervention: 250 mg furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 mg furosemide
Number of subjects: 12
Study: 28837593

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Work Readiness Questionnaire
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Quality-of-Life Scale total scores
Number of subjects: 208
Study: 25840035

Group type: EXPERIMENTAL
Intervention: Standard care plus daily tailored text messages for 6 months
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care (one-on-one counseling sessions with a dietitian and a physician)
Number of subjects: 124
Study: 23359039

Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop delivery
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard insulin-pump therapy (control)
Number of subjects: 15
Study: 21982658

Group type: EXPERIMENTAL
Intervention: Primary PCI for STEMI
Number of subjects: 3343
Study: 18056753

Group type: EXPERIMENTAL
Intervention: Education and counseling on pain management, physical activity, and exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional physical therapy intervention (comparison group)
Number of subjects: 34
Study: 17176190

Group type: EXPERIMENTAL
Intervention: Self-guided group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Instructor-encouraged group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 14668186

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in a 0.04 mol/l solution in Plegisol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Crystalloid (Plegisol) cardioplegia
Number of subjects: 35
Study: 10969368

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 126

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 126
Study: 8648016

Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol sulfate (4 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1510511

Group type: EXPERIMENTAL
Intervention: Warm heart surgery technique (normothermic group)
Number of subjects: 204
Study: 6643332

Group type: EXPERIMENTAL
Intervention: Amikacin 7.5 mg/kg by iv infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tobramycin 1 mg/kg
Number of subjects: 58
Study: 31697304

Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.625 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg
Number of subjects: 61
Study: 30817604

Group type: EXPERIMENTAL
Intervention: Supportive group psychotherapy (SGP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 160
Study: 28118231

Group type: COMPARATOR
Intervention: Dexamethasone 5 mg (control group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dexamethasone 15 mg (study group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (5 mg and 15 mg)
Number of subjects: 68
Study: 25994974

Group type: EXPERIMENTAL
Intervention: Neck stretching exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual headache management
Number of subjects: 60
Study: 24290111

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (vitamin D3) 5000 IU/d for 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single dose of 150,000 IU cholecalciferol
Number of subjects: 40
Study: 21674388

Group type: EXPERIMENTAL
Intervention: Neuro-Rehabilitation-roBot (NeReBot) used in substitution of standard proximal upper-limb rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard proximal upper-limb rehabilitation)
Number of subjects: 0
Study: 19435200

Group type: EXPERIMENTAL
Intervention: Galavit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 16686761

Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 343

Group type: COMPARATOR
Intervention: CYA/MMF
Number of subjects: 343
Study: 15452302

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1250 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: IV methylprednisolone (1 gram)
Number of subjects: 16
Study: 11252581

Group type: EXPERIMENTAL
Intervention: Cisatracurium (2xED95, group C2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium (4xED95, group C4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium (2xED95, group P)
Number of subjects: 60
Study: 8315423

Group type: EXPERIMENTAL
Intervention: Doxorubicin (500 mg/m2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (120 mg/m2)
Number of subjects: 35
Study: 3575355

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 37.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29880342

Group type: EXPERIMENTAL
Intervention: Sirolimus (sirolimus, tacrolimus, prednisone)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Mycophenolate (mycophenolate, tacrolimus, prednisone)
Number of subjects: 23
Study: 28850488

Group type: EXPERIMENTAL
Intervention: Cervical fusion operation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Multimodal rehabilitation
Number of subjects: 49
Study: 24442560

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1479
Study: 23433739

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab
Number of subjects: 549

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 549
Study: 21338241

Group type: EXPERIMENTAL
Intervention: Immigrant residents (IR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Host residents (HR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and income
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and alcohol drinking
Number of subjects: 0
Study: 18840372

Group type: EXPERIMENTAL
Intervention: Test formulation of 30 mg sublingual ketorolac
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reference formulation of 30 mg sublingual ketorolac
Number of subjects: 27
Study: 16737621

Group type: EXPERIMENTAL
Intervention: Wide-margin group (distal margin of 2 cm, proximal margin of 1 cm)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Narrow-margin group (resection margin < 1 cm)
Number of subjects: 152
Study: 12844375

Group type: EXPERIMENTAL
Intervention: 24 mmol slow-release KCl/d (n=30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 59
Study: 10563527

Group type: EXPERIMENTAL
Intervention: Natural interferon-alphaN3 with N-acetyl cysteine 1200 mg/day and vitamin E 600 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Natural interferon-alphaN3 alone
Number of subjects: 120
Study: 8939377

Group type: EXPERIMENTAL
Intervention: Supraperiosteal flap technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Push-back technique (Wardill, 1937)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mucoperiosteal technique
Number of subjects: 0
Study: 1438670

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 25
Study: 2856817

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study: 30690400

Group type: EXPERIMENTAL
Intervention: Directed air tower (DAT) sprayer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-headed fan tower (MFT) sprayer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Axial fan airblast (AFA) sprayer
Number of subjects: 0
Study: 29580134

Group type: EXPERIMENTAL
Intervention: 1 × 30s (simple set of 30 seconds)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 × 10s (multiple sets of 10 seconds)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 × 10s (simple set of 10 seconds)
Number of subjects: 36
Study: 27382136

Group type: EXPERIMENTAL
Intervention: Vinyl banner displaying vegetable characters
Number of subjects: 22026

Group type: EXPERIMENTAL
Intervention: Combination of television segments and vinyl banners
Number of subjects: 22026

Group type: EXPERIMENTAL
Intervention: Vinyl banner
Number of subjects: 22026
Study: 24887540

Group type: EXPERIMENTAL
Intervention: Blended current (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pure coagulation current (group B)
Number of subjects: 84
Study: 23230666

Group type: EXPERIMENTAL
Intervention: Micro-invasive surgical therapy (endoscope-assisted posterior operation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional surgical therapy (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 20434047

Group type: EXPERIMENTAL
Intervention: Thromboembolic vessel disease (TEVD)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both groups (TEVD and ICH)
Number of subjects: 46
Study: 18758677

Group type: EXPERIMENTAL
Intervention: Acupuncture together with tricyclic antidepressants and exercise (n=34)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tricyclic antidepressants and exercise only (n=24)
Number of subjects: 58
Study: 16496831

Group type: EXPERIMENTAL
Intervention: Individualised education intervention (EI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard preadmission program (SP)
Number of subjects: 93
Study: 14645186

Group type: EXPERIMENTAL
Intervention: Counselling (routine pre-IVF counselling)
Number of subjects: 141
Study: 10476944

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 50 IU
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 15 IU
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 150 IU
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 8982576

Group type: EXPERIMENTAL
Intervention: Careful long-term follow-up and evaluation of medical interventions in the neonatal period
Number of subjects: 0
Study: 1487471

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6723694

Group type: EXPERIMENTAL
Intervention: Slow-release mexiletine 360 mg 12 hourly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional mexiletine 200 mg 8 hourly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow-release mexiletine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional mexiletine
Number of subjects: 12
Study: 30672623

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg fixed interval (FI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg fixed interval (FI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Secukinumab (FI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 52
Study: 29857882

Group type: EXPERIMENTAL
Intervention: Herbal acupoint therapy (HAT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study: 26687616

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 76
Study: 23332626

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (Ca/VitD)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study: 22791289

Group type: EXPERIMENTAL
Intervention: Bortezomib/thalidomide/dexamethasone (VTD)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Thalidomide/dexamethasone (TD)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Bortezomib/thalidomide/dexamethasone (VTD) post-ASCT
Number of subjects: 386

Group type: COMPARATOR
Intervention: Thalidomide/dexamethasone (TD) post-ASCT
Number of subjects: 386

Group type: COMPARATOR
Intervention: Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) post-ASCT
Number of subjects: 386
Study: 20195673

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g/12 h) plus amikacin (15 mg/kg/day)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin
Number of subjects: 190
Study: 17624617

Group type: EXPERIMENTAL
Intervention: Project Northland intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed-program control communities
Number of subjects: 0
Study: 15932660

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no fluvastatin)
Number of subjects: 60
Study: 11883790

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (30 g/300 ml/30 min)
Number of subjects: 0
Study: 10073605

Group type: EXPERIMENTAL
Intervention: Patients with glomerulonephritis (GN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with diabetic nephropathy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Microdissected glomeruli from patients with GN
Number of subjects: 37
Study: 7560615

Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction within 42 days
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction between 43 and 365 days
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: Nonfatal reinfarction between 366 days and 3 years
Number of subjects: 3339